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A triphenylethylene nonsteroidal 
seRM attenuates cervical cancer 
growth
Neeraj Chauhan1,4, Diane M. Maher2, Murali M. Yallapu1,4, Bilal B. Hafeez1,4, Man M. singh3, 
Subhash C. Chauhan  1,4 & Meena Jaggi1,4
selective estrogen receptor modulator drug molecules of triphenylethylene family have gained 
considerable attention as anti-cancer agents. Despite recent advances in screening and development 
of HPV vaccines, cervical cancer remains one of the deadliest malignancies as advanced stage 
metastatic disease is mostly untreatable, thus warrants newer therapeutic strategies. Ormeloxifene 
(ORM) is a well-known SERM of triphenylethylene family that has been approved for human use, thus 
represents an ideal molecule for repurposing. In this study, we for the first time have demonstrated 
the anti-cancerous properties of ormeloxifene in cervical cancer. Ormeloxifene efficiently attenuated 
tumorigenic and metastatic properties of cervical cancer cells via arresting cell cycle at G1-S transition, 
inducing apoptosis, decreasing PI3K and Akt phosphorylation, mitochondrial membrane potential, 
and modulating G1-S transition related proteins (p21, cyclin E and Cdk2). Moreover, ORM repressed 
the expression of HPV E6/ E7 oncoproteins and restored the expression of their downstream target 
tumor suppressor proteins (p53, Rb and PTPN 13). As a result, ormeloxifene induces radio-sensitization 
in cervical cancer cells and caused potent tumor growth inhibition in orthotopic mouse model. Taken 
together, ormeloxifene represents an alternative therapeutic modality for cervical cancer which may 
have rapid clinical translation as it is already proven safe for human use.
Cervical cancer stands at the fourth rank among most common and deadly malignancies in women globally. 
In the year of 2018, there are 13,240 new cases and 4,170 death cases of cervical cancer estimated in the Unites 
States1. Incidence rates remain higher in less developed countries (15.7%), mainly in Eastern (42.7%), Middle 
(30.6%) and South Africa (31.5%), than more developed countries (9.9%)2.
Cervical cancer is primarily associated with persistent infection of high risk Human Papillomavirus (HPV)3. 
HPVs are circular, double stranded DNA viruses that consist of approximately 8000 base pairs4 and are the most 
common type of sexually transmitted virus infection5. There are more than 100 identified human papillomaviruses 
which are divided into two categories – High Risk and Low Risk6. Persistent infection of any of these 13 High risk 
HPV’s (HVP 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59 and 66) can result in the progression of cervical cancer7. HPV 16 
and 18 are the most shared (transmitted) type of HPVs and account for about 70% of invasive cervical cancer cases8.
Malignant cervical cancer cells specifically express two viral oncoproteins HPV E6 and E79. HPV E6 and E7 
are known to cause genomic alterations resulting in gain or loss of function of genes in various cancers including 
cervical cancer10,11. E6 and E7 disturb the functions of p53 (protein 53) and Rb (Retinoblastoma protein), two 
tumor suppressor proteins. Both proteins regulate cell cycle progression and excessive cell proliferation. The E6 
binds to p53 and degrades it by proteosomal degradation12. Whereas the E7 oncoprotein binds to Rb, causing its 
degradation and leading to the induction of cell growth and gene promoting DNA synthesis13.
PI3K-Akt is a cell survival pathway which is responsible of many cellular functions such as cell proliferation, cell 
survival and cell cycle progression in variety of cancers14 and is activated by HPV E6 and E715. Akt becomes phos-
phorylated at serine and threonine residuals by the overexpression of PI3K16 and thus, gets activated for the further 
initiation of apoptosis cascade17. Human cervical cancer tissues samples express increased levels of pAkt18, there-
fore, PI3K-Akt signaling pathway has gained much attention as potential therapeutic targets for cervical cancer19.
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Though HPV is the most common factor of cervical cancer, yet alone it is not sufficient to develop cervical 
cancer and requires several chromosomal changes and genetic damages/alterations, including viral DNA inte-
gration itself and mutations mainly in TP53 and Rb20–22, along with other risk factors such as smoking, multiple 
sexual partners, early sexual debut and low socioeconomic status23. Genetic aberrations play a pivotal role in the 
progression of cervical cancer20. Two significant and recurrent HPV 16/18 viral DNA integrations occur specif-
ically at 8q24 and 12q15 chromosomal locations24–27. Some other frequently occurring chromosomal alterations 
that are not even associated to p53 mutation are 3p14–22, 4p16, 5p15, 6p21–22, 11q23, 17p13.3, 18q12–22 and 
19q1328,29. Among females, cigarette smoking has two times higher risk of having cervical cancer than those who 
do not smoke30. A well-known cigarette smoke carcinogen, BaP (Banzo[a]pyrene) increases the expression levels 
of HPV oncoproteins E6 and E7 in cervical cancer cells31. Epidemiology of cervical cancer suggests that having 
multiple sexual partners and early sexual debut increase the risk for HPV infection and development of cervical 
cancer among women32,33.
In many developed countries Pap Smear Screening (Pap test) to detect and subsequently remove pre-cancerous 
lesions has greatly reduced the incidences of cervical cancer34. HPV testing is also available to detect high risk 
HPVs and can be used independently or in combination with Pap test35. Current available treatment modalities 
for the management of cervical cancer are disease stage dependent; early stage patients are mainly advised sur-
gery or radiotherapy whereas late stages of cervical cancer are tackled by radiation along with cisplatin based 
chemotherapy36.
Ormeloxifene (Centchroman), C30H35O3N.HCl, is a non-steroidal, non- hormonal anti- estrogen oral con-
traceptive for human use that is taken once per week37. Ormeloxifene belongs to triphenylethylene family38 and 
members of this family are known to have potent anti-cancer properties39–43. Ormeloxifene has been used as an 
anti-neoplastic agent in MCF-7 and MDA-MB-231 Estrogen Receptor (ER ± ve) Human Breast Cancer Cells 
(HBCCs)44. Additionally, in a phase II clinical trial of advanced stage breast cancer, ormeloxifene has shown 
profound anti-cancer efficacy with overall 38.7% response rate in female patients and 6 month median duration 
of response37.
In this present study, we assessed ormeloxifene’s anti-cancerous properties in cervical cancer cells and mouse 
model. We report that ormeloxifene effectively inhibits the cellular proliferation, growth and motility, induces 
apoptosis through mitochondrial intrinsic pathway and arrests cell cycle progression in cervical cancer cells. 
Moreover, ormeloxifene significantly decreases/inhibits the oncogenic signaling of HPV E6/7 and PI3K-Akt path-
way and upregulates the tumor suppressor signaling by restoring the expression levels of p53, Rb and PTPN13. 
Additionally, ormeloxifene radio-sensitizes cells in vitro and exhibits excellent anti-tumor activity in orthotopic 
mice model of cervical cancer. Findings from this study, collectively, suggest that ormeloxifene has great potential 
to become a novel therapeutic agent for the management of cervical cancer.
Results
Ormeloxifene treatment inhibits cellular growth and motility of various cervical cancer 
cells. To determine the effect of ormeloxifene on cell growth of various cervical cancer cells, we performed cell 
proliferation (MTS) assays with Caski and SiHa (HPV positive) (Fig. 1A) and, C33A and HT3 (HPV negative) 
(Fig. S1A). Cells were treated with ormeloxifene at micro-molar ranges for 48 hours. All four cell lines showed a 
significant decrease in a dose-dependent manner and a drastic inhibitory effect was found between 20 µM and 
25 µM doses. A growth kinetic experiment was also performed using xCELLigence RTCA system (Fig. 1B) to 
confirm ormeloxifene’s effect on cellular growth of Caski and SiHa cell lines with respect to time. Colony forming 
ability is an essential property of cancerous cells. Thus, we assessed colony forming assays to determine the long-
term effect of ormeloxifene on cervical cancer cell lines. Ormeloxifene showed a significant effect on clonogenic 
potential of all tested cervical cancer cell lines (Figs. 1C,D,S1B,C) in a dose-dependent manner. We also analyzed 
the metastatic properties of cervical cancer cells after ormeloxifene treatment with cell migration and invasion 
assays using Boyden chamber migration and Boyden chamber matrigel invasion assays. Both Caski and SiHa 
cells showed an inhibition of migration and invasion (Fig. 1E) with an increase in ormeloxifene concentration. 
A real time kinetic assessment for migration and invasion was also performed using xCELLigence RTCA system 
(Fig. 1F) to confirm ormeloxifene’s effect on metastasis of Caski and SiHa cells, and results were consistent with 
the Boyden chamber assays. Furthermore, the migratory ability of cells was analyzed by using an agarose bead 
assay (Fig. S1D). Ormeloxifene treatment again showed an inhibition of migration in dose and time dependent 
manner in both cell lines.
Ormeloxifene induces cell death through mitochondrial intrinsic pathway. Decreased mitochon-
drial membrane potential (MMP) is a clear sign of induction of apoptosis through the mitochondrial intrin-
sic pathway. We observed cells by microscopy and also performed flow cytometry using TMRE (Tetramethyl 
rhodamine ethyl ester, Invitrogen) stain to detect the depolarization of mitochondrial membrane in Caski and 
SiHa cells. Ormeloxifene significantly decreases MMP of both cell lines (Fig. 2A,B). Cells were also observed 
under phase contrast microscopy to visualize signs of apoptosis, such as cell membrane blebbing and shrink-
age (Fig. S2A). Furthermore, we confirmed ormeloxifene’s ability to induce apoptosis by staining the cells with 
Annexin V-7AAD dyes. Both cell lines showed a marked increase in the percentage of Annexin V positive cell 
population (Fig. 2C,D) at 20 and 25 µM concentrations after 24 hours of treatment. Under stress conditions, such 
as drug treatment or radiation, tumor cells are known to generate reactive oxygen species (ROS) due to the oxi-
dative stress. Production of reactive oxygen species is one of the key signals that leads to apoptosis. Therefore, we 
used DCFH-DA (dichlorodihydrofluorescein diacetate) stain to detect the amount of reactive oxygen species gen-
eration after ormeloxifene treatment in Caski and SiHa cell lines. DCFH-DA is commonly used to detect intracel-
lular production of H2O2. After 24 hours of ormeloxifene treatment at 25 µM concentration both cell lines showed 
elevated levels of H2O2 generation when compared to vehicle control ETOH as confirmed by higher intensity 
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levels of DCFH-DA stain (Fig. 2E). We further validated ormeloxifene’s ability to block cell cycle progression by 
performing the cell cycle arrest assay to determine the cell population at different phases of cell cycle. Caski and 
SiHa cell lines were treated with 10, 20 and 25 µM of ormeloxifene for 24 hours and stained with Propidium Iodide 
(PI). Cells showed a blockage of cell cycle progression at G1-S transition (Figs. 2F,S2B).
Ormeloxifene modulates the expression of cell cycle regulatory proteins and PI3K-Akt path-
way. We further confirmed the cell cycle arrest at G1-S transition with immunoblotting by probing for two 
transition related molecules Cyclin E and its dependent kinase; cyclin dependent kinase 2 (Cdk2) and also for p21 
which is a known repressor of this transition phase. Ormeloxifene significantly decreased the expression of Cyclin 
E and Cdk2 and increased the expression of p21 at 20 µM concentration when compared to the vehicle control 
ETOH (Fig. 3A top panel). PI3K-Akt cell survival oncogenic pathway is overly expressed in cervical cancer cells. 
The pathway is required for cell cycle progression from G1 phase to S phase. Inhibition of PI3K-Akt pathway is 
an important tool for developing the treatment strategies for cervical cancer. We utilized immunoblotting assay 
to evaluate the inhibitory effects of ormeloxifene on PI3K-Akt pathway. Ormeloxifene slightly decreased the total 
Akt expression but pAkt, which is the phosphorylated and active form of Akt, and PI3K were decreased markedly 
(Fig. 3A bottom panel). We also quantified the band intensities of these immunoblots (Fig. 3B through 3G).
Ormeloxifene decreases the expression of HPV E6 and E7. Oncogenes E6 and E7 are responsible for 
continuous cell division which promotes the development of cervical cancer. An effect on the expression of human 
papillomavirus E6 and E7 is an important consideration for cervical cancer treatment. Quantitative RT-PCR was 
performed to determine the expression of HPV oncogenes E6 and E7 in Caski cells. Ormeloxifene significantly 
inhibited the expression of E6 and E7 after 6 hours of ormeloxifene treatment (10 and 20 µM doses) (Fig. 4A,B). The 
indicated treatment was compared with vehicle control ETOH. We also assessed the downregulation of oncogenic 
Figure 1. Ormeloxifene inhibits cell proliferation and motility. (A) Ormeloxifene decreases cellular 
proliferation of Caski and SiHa cells. Caski and SiHa cells were treated with ormeloxifene (10, 20, 25 µM) for 
48 hours and MTS method was used to determine proliferation and absorbance was measured at 490 nm. 
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n = 3. *p < 0.05. (B) Growth 
kinetics through xCELLigence RTCA. Caski and SiHa cell lines were treated with 20 µM ormeloxifene and 
growth kinetics (rate of real time proliferation) was measured. (C,D) Ormeloxifene inhibits clonogenic 
potential of cells. (C) Cells showed inhibited colony forming ability after 15 days of ormeloxifene treatment. 
Results were normalized to the ETOH control. Error bars show SEM, n = 3. *p < 0.05. (D) Qualitative 
representation of inhibited clonogenecity of cells. Images were taken at 200X. (E) Ormeloxifene decreased the 
cellular migration and invasion. Cells were treated with ormeloxifene for 24 hours and images were taken at 
100X. Both cells show clear inhibition of motility and invasion confirmed by Boyden chamber method. (F) 
Motility kinetics through xCELLigence RTCA. Real time migratory and invasive properties of Caski and SiHa 
cells were also confirmed using xCELLigence system.
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signaling at the translational level by performing immunoblotting. Both oncoproteins showed a marked reduction 
in the expression level compared to the vehicle control ETOH (Fig. 4C top panel). The oncogenic properties of 
HPV E6 and E7 are increased when E6 and E7 bind to the tumor suppressor proteins p53, Rb and PTPN13. These 
tumor suppressor proteins p53, Rb and PTPN13 are not mutated in HPV positive cervical cancer cells but are 
inactivated (or low in expression/function)45,46. Ormeloxifene’s effect on these tumor suppressing molecules was 
determined by the immunoblotting assays. We treated Caski cervical cancer cells with 10 and 20 µM concentra-
tions of ormeloxifene for 24 hours and probed for these three tumor suppressor proteins. We observed a slight but 
noticeable increase in the expression of wild type p53 but Rb and PTPN13 proteins showed a marked increase in 
the expression after ormeloxifene treatment at 20 µM dose (Fig. 4C bottom panel), band intensities for these blots 
were also measured (Fig. 4D through 4H).
Figure 2. Ormeloxifene induces apoptosis and arrests cell cycle of cervical cancer cells. Ormeloxifene 
decreases mitochondrial membrane potential (MMP). (A) Cells were stained with TMRE dye for 20 mins at 
37 °C and next treated with ormeloxifene for 24 hours to detect the healthy mitochondria. Representation of 
qualitative images showed decreased TMRE stain signifying reduced MMP, images were taken at 200X. (B) 
Flow cytometry results also showed a reduction in MMP (decreased TMRE fluorescence level). Results were 
normalized to the ETOH control. Error bars show SEM, n = 3. *p < 0.05. Ormeloxifene induces apoptosis. (C) 
Cells were treated with ormeloxifene for 24 hours and analyzed by flow cytometry using Annexin V and 7AAD 
dyes. (D) Graphical representation of flow cytometry data for Annexin V positive cells (early apoptosis). Error 
bars show SEM, n = 3. *p < 0.05. (E) Generation of reactive oxygen species (ROS). Cells were treated with 
25 µM ormeloxifene and stained with DCFH-DA dye. Flow cytometry data represented an elevated levels of 
DCFH-DA dye which denotes generation of ROS. Error bars show SEM, n = 3. *p < 0.05. (F) Cell cycle was 
arrested at G1-S transition. Cells were treated with ormeloxifene for 24 hours, stained with PI dye and analyzed 
by flow cytometer and ModFit software for cell cycle analysis. ± shows SEM, n = 3. *p < 0.05.
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Ormeloxifene treatment induces radio-sensitization in cervical cancer cells. We performed 
short-term and long-term studies to analyze ormeloxifene’s effect on radio-sensitization in Caski cells. We 
observed that after 24 hours of radiation, number of live cells significantly decreased with 6 hours pretreatment of 
ormeloxifene when compared with radiation alone and ormeloxifene alone treatment groups (Fig. 5A,B). These 
results were consistent with long-term treatment of radiation. Pretreatment of ormeloxifene significantly sensi-
tized Caski cells to radiation as confirmed by decreased number of colonies when compared to radiation alone 
and ormeloxifene alone treated groups (Fig. 5C,D).
Ormeloxifene effectively inhibits cervical cancer tumorigenesis in orthotopic mice model. It 
was important to test ormeloxifene in vivo after observing its anti-cancerous properties in in vitro models. In 
order to evaluate anti-tumorous efficacy of ormeloxifene, we generated an orthotopic cervical cancer mouse 
model using female nude mice. For this mouse model development, we used HPV positive Caski cervical cancer 
cells and injected directly into the cervix of these female nude mice. 6 mice were taken in each treatment group 
(PBS and ORM; 2 treatment groups). Mice started developing tumors within 15–20 days, and once the tumor 
size was approximately 100 mm3, ormeloxifene and its vehicle control PBS were administered by intra-peritoneal 
injections. The study was terminated when the control group tumor size reached around 1000 mm3. At termina-
tion, mice were euthanized, and tumors were dissected from both groups (Fig. 6A). It was observed that ormel-
oxifene increased the overall mice survival rate (Fig. 6B) when compared to its vehicle control PBS group. During 
the entire study tumor size/volume was measured. Ormeloxifene significantly decreased the tumor volume when 
compared to its vehicle control PBS (Fig. 6C). We also measured the tumor weight after dissection and results sug-
gested that ormeloxifene reduced the tumor weight markedly when compared to its vehicle control PBS (Fig. 6D).
Discussion
Despite of having various preventative modalities including vaccines and screening34, cervical cancer is a deadly 
malignancy of women3. Advanced stages of cervical cancer remain untreatable because of many modulations at 
the cellular and molecular levels, therefore, cells become more invasive and show resistance towards chemo and 
radiotherapy36,47. Thus, newer therapeutic means are highly desirable that provide protection against metastasis 
Figure 3. Ormeloxifene modulates the expression of cell cycle regulatory proteins and decreases PI3K/Akt 
pathway. (A) Immunoblots for protein expression. Caski cells were treated with ormeloxifene for 24 hours and 
immunoblots were preformed to detect p21, CdK2, Cyclin E, Akt, pAkt and PI3K proteins. β -actin was used as 
a loading control. All full-length blots are presented in Supplementary Information. Band quantifications of (B) 
p21, (C) Cdk2, (D) Cyclin E, (E) Akt, (F) pAkt, and (G) PI3K. Band quantitation was done by using GelQuant 
software. Band intensity was normalized to β -actin and scaled to the ETOH control. Bars = Relative Expression 
Level, Error bars show SEM, n = 3. *p < 0.05.
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and chemo/radio-resistance. Currently, repurposing of the molecules which are already in use has become a new 
attraction48. Considering the potential of repurposing a drug that is already in use, we investigated the therapeu-
tic potential of ormeloxifene in this study. Ormeloxifene has been in use for its birth control proposes for more 
than two decades in India49. Ormeloxifene targets high proliferative decidule cells in the endometrium and has 
been reported to be safe50,51. Recently, studies from other groups and our lab have exhibited that ormeloxifene has 
anti-cancerous activities against breast, head and neck, ovarian, pancreatic and leukemia cancers52.
Uncontrolled cell proliferation/growth and inability to have programmed cell death are the major causes of 
cancer development53. In this study, we show that ormeloxifene decreases cellular proliferation of four different 
cell lines, HPV positive and negative, with a short-term (48 hours) treatment of ormeloxifene as confirmed by 
MTS assay (Figs. 1A,S1A). Results from xCELLigence real time growth kinetic assay are also consistent with MTS 
data findings (Fig. 1B). Ormeloxifene also inhibits the clonogenic potential of all four cell lines with a long-term 
treatment of about 14/15 days (Figs. 1C,D,S1B,S1C). These results are consistent with previous work showing 
ormeloxifene’s anti-proliferative potential40,42. When cells go under drug treatment, they exhibit apoptosis like 
signs, ormeloxifene treatment alters the morphology of Caski and SiHa cells and shows the apoptosis like signs 
such as membrane blebbing, cell shrinkage and rounding of shape (Fig. S2A)54. Apoptosis is a major event that 
occurs in response to many anti-cancer drugs54. Apoptosis consists of two different pathways, namely extrinsic 
and intrinsic. Intrinsic apoptotic death cascade involves the depolarization of mitochondrial membrane as a first 
event of the cascade that further leads to the activation of caspases and results in PARP cleavage55. Ormeloxifene 
treatment for 24 hours affects the mitochondrial membrane depolarization as confirmed by decreased mito-
chondrial membrane potential assessed by TMRE staining through fluorescent microscopy and flow cytometer 
(Fig. 2A,B). Annexin V-7AAD staining is another method to detect the apoptotic cell population. Ormeloxifene 
treatment for 24 hours results in increased apoptotic population of Caski and SiHa cell lines (Fig. 2C,D), also 
ormeloxifene activates ROS generation in these cells (Fig. 2E), which indicates that ormeloxifene has the potential 
to become anti-proliferative/growth molecule for cervical cancer.
Excessive cell cycle progression is a key property of cancerous cells and controlled by many activated cyclins 
and their dependent kinases56,57. Ormeloxifene treatment plays an inhibitory role in cell cycle progression of 
Caski and SiHa cells. It arrests cell cycle in both cell lines at G1-S transition (Figs. 2F,S2B) and decreases the 
expression of Cyclin E and its dependent kinase CDk2 (Fig. 3A top). Cyclin E and Cdk2 help cells to progress 
from G1 phase to S phase56. PI3K-Akt pathway plays an important role in cell growth and cell cycle progression58. 
Figure 4. Effects of ormeloxifene on HPV infection. Ormeloxifene decreases (A) HPV E6 and (B) E7 mRNAs. 
Caski cells were treated with ormeloxifene for 6 hours and mRNA levels of HPV E6 and E7 were determined by 
quantitative PCR. Expression levels were normalized to a house keeping gene (β-2-Microgloblin) and scaled 
to the vehicle control (ETOH). Bars = Relative Expression Level, Error bars show SEM, n = 3. *p < 0.05. (C) 
Ormeloxifene inhibits HPV E6 and E7 proteins and upregulates tumor suppressor proteins. Caski cells were 
treated with ormeloxifene for 24 hours and western blots were preformed to detect HPV E6 and E7,  
wt-p53, Rb and PTPN13 proteins. β -actin was used as a loading control. All full-length blots are presented in 
Supplementary Information. Band quantifications of (D) E6, (E) E7, (F) wt-p53, (G) Rb and (H) PTPN13. Band 
quantitation was done by using GelQuant software. Band intensity was normalized to β -actin and scaled to the 
ETOH control. Bars = Relative Expression Level, Error bars show SEM, n = 3. *p < 0.05.
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In accordance with previous findings40, we show that ormeloxifene downregulates the PI3K-Akt pathway in cer-
vical cancer cells as shown by decreased expression levels of PI3K, Akt and pAkt (Fig. 3A bottom). Ormeloxifene 
further increases the downstream target of this pathway, p21 (Fig. 3A top), which is also a known inhibitor of 
cell cycle progression. Cancer cells show enhanced motility and invasion which help cancer cells migrate from 
one organ to another and this is how cancer spreads59. Molecules that inhibit migratory and invasive property of 
cancer cells are strong candidates for having anti-cancerous properties. We utilized various techniques including 
agarose bead assay (Fig. S1D), Boyden chamber migration and invasion assays (Fig. 1E), and xCELLigence real 
time kinetic studies (Fig. 1F) to confirm ormeloxifene’s effect on cellular motility of Caski and SiHa, results reveal 
that cells become less motile and invasive with ormeloxifene treatment for 24 hours.
Persistent HPV infection is required for the progression of cervical cancer60, so we intended to assess ormel-
oxifene’s effect on HPV E6 and E7 expression. Ormeloxifene successfully inhibits the mRNA levels of HPV E6 
and E7 with 6 hours of treatment (Fig. 4A,B), the downregulation also continued to the translational levels as 
ormeloxifene decreases the expression of HPV E6 and E7 oncoproteins with 24 hours treatment (Fig. 4C top). 
HPV E6 and E7 deregulate the cell cycle by inactivating tumor suppressor proteins p53, Rb and PTPN1312,13,61, 
interestingly, ormeloxifene upregulates the expression of these three proteins (Fig. 4C bottom). These findings 
suggest that ormeloxifene not only decreases the oncogenic signaling but also increases the tumor suppressing 
signaling, thus, have potent anti-HPV properties in cervical cancer cells. Additionally, we observed that ormel-
oxifene sensitizes cervical cancer cells to radiation (Fig. 5A–D) and shows great anti-tumor efficacy (Fig. 6A–D).
Available literature suggests that ormeloxifene has strong anti-neoplastic properties in MCF-7/ MDA MB-231 
Estrogen Receptor (ER ± ve) Human Breast Cancer Cells (HBCCs)62,63. Moreover, ormeloxifene works excellent 
in combinational therapies as well with curcumin or resveratrol64 and with glycine soya65 against breast cancer; 
results from these studies suggest that ormeloxifene works via both ER dependent and ER independent mecha-
nisms and also it seems to work through various other pathways such as PI3K-Akt, STAT3 and SHH40–42 which 
are responsible for proliferation and cell cycle progression. In addition, data presented in this study clearly indi-
cates that ormeloxifene modulates HPV E6/E7 signaling and PI3K-Akt pathway in cervical cancer. Thus, collec-
tively this information denotes that ormeloxifene is a multifunctional/multifaceted molecule and targets different 
signaling pathways in different types of cancers. Previously published studies show that HPV E6/E7 activates 
and alters the function of phosphorylated form of Akt (serine/threonine) in both Rb dependent15 and independ-
ent66 manner. Therefore, this can be interpreted that ormeloxifene driven inactivation of PI3K-Akt signaling in 
this study is HPV E6/E7 mediated but future experiments are warranted to determine the underline molecular 
Figure 5. Ormeloxifene sensitizes Caski cells to radiation. Ormeloxifene radio-sensitizes cells and decreases 
cell proliferation. (A) Caski cells were pretreated with 10 µM ormeloxifene for 6 hours and next exposed to 
4Gy radiation. Live cells were counted using a coulter counter. Error bars show SEM, n = 3. *p < 0.05. (B) 
Representative images of ormeloxifene and radiation treated cells. Images were taken at 100X. Ormeloxifene 
radio-sensitizes cells and decreases colony forming ability. (C) Caski cells were pretreated with 2, 4, 6 and 8 µM 
ormeloxifene for 6 hours and next exposed to 4Gy radiation. After 14 days, cells with combination treatment 
showed fewer colonies than compared to ormeloxifene and radiation alone. Error bars show SEM, n = 3. 
*p < 0.05. (D) Images represent inhibited clonogenic potential. Images were taken at 200X.
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mechanism for ORM’s action in cervical cancer as ormeloxifene has been reported to work through both HPV 
dependent and independent mechanisms.
Conclusion
To conclude, the present study clearly shows that ormeloxifene significantly decreases cell growth, migration, 
invasion, arrests cell cycle and induces apoptosis through mitochondrial death cascade. Also, ormeloxifene 
downregulates PI3K-Akt cell survival signaling. Interestingly, ormeloxifene reduces the expression of HPV E6 
and E7, and as a result of this inhibited oncogenic signaling it further restores the tumor suppressors p53, Rb 
and PTPN13. Moreover, it radio-sensitizes cells and improves life expectancy of tumor bearing mice. Therefore, 
collectively, findings from this study suggest that ormeloxifene has great potential to become a novel treatment 
strategy for overall cervical cancer management.
Material and Methods
Chemicals and antibodies. All chemicals and reagents were purchased from Sigma-Aldrich Corporation 
(St. Louis, MO, USA) and all other cell culture consumables were purchased from Corning life sciences 
(Tewksbury, MA, USA), unless otherwise mentioned. Specific antibodies of HPV 16 E6/E7 were procured from 
Abcam (Cambridge, MA, USA), antibodies of PI3K, Akt, pAkt, Rb, PTPN13, p21, Cyclin E, Cdk2 and β-actin 
were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA) and p53 was purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Details on Ormeloxifene (ORM) was kindly provided by M.M.S.
Cell culture. All cells (HPV positive Caski and SiHa, HPV negative C33A and HT3) were obtained from 
ATCC. SiHa and C33A were cultured in DMEM supplemented with 4500 mg/L glucose, 4.00 mM L- Glutamine, 
10% heat inactivated FBS (Atlantic Biologicals, Lawrenceville, GA, USA), 1% (5 ml) sodium pyruvate, 1% 
(5 ml) nonessential amino acids and 1% (5 ml) 1X antibiotic/antimycotic (Sigma-Aldrich, St. Louis, MO, USA). 
Caski cells were maintained in RPMI medium containing 2.05 mM L-Glutamine, 10% heat inactivated FBS 
and 1% (5 ml) 1X antibiotic/antimycotic. HT3 cells were grown in McCoy’s 5A medium accommodated with 
L-Glutamine, 10% heat inactivated FBS and 1% (5 ml) 1X antibiotic/antimycotic. All cells were incubated at 37 °C 
in a humidified atmosphere of 5% CO2.
Figure 6. Ormeloxifene inhibits tumor growth in cervical cancer orthotopic mice model. Orthotopic mice 
model was generated by injecting Caski cells direct into the cervix of female nude mice. (A) Images represent 
mice from different treatment groups. (B) Ormeloxifene increased overall life expectancy and mice survival 
than compared to its vehicle control PBS. (C,D) Ormeloxifene also showed a marked reduction in tumor 
volume and weight than compared to PBS. Error bars show SEM, n = 6. *p < 0.05.
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Cell proliferation. We used four different cervical cancer cell lines; Caski, SiHa, C33A and HT3. All cell lines 
were seeded at 5000 per well in 96-well plates and allowed to attach overnight. Following day, all cervical cancer cell 
lines were treated with 10, 20 and 25 µM concentrations of ormeloxifene for 48 hours. After 48 hours, the CellTiter96 
Aqueous One Solution (Promega, Madison, WI, USA) was added to 96-well plates (20 µL/well) for 2 hours incubation 
at 37 °C and absorbency was measured at 490 nm. Proliferation results were normalized to control wells treated with 
vehicle control ETOH. The experiment was performed in 6 replicates and repeated for three times.
Clonogenic potential. All cervical cancer cell lines were seeded at 200/well (Caski, SiHa and C33A) and 
500/well (HT3) in 6-well plates and allowed to adhere overnight. Following day, cells were treated with 2.5, 5 and 
10 µM of ormeloxifene and maintained for next 15 days. On the 15th day cells were washed, fixed in cold methanol 
and stained with hematoxylin (Thermo Fisher, MA, USA). Visible colonies (~50 cells) were counted and pre-
sented as compared to the vehicle (ETOH) control. Experiment was done in 3 replicates and repeated for 3 times.
Boyden chamber cell migration and invasion. Cell migration assay was performed in a 96-well format 
HTS transwell plate from Corning. Caski and SiHa cells were serum starved for overnight and next day, plated at 
30,000 cells/well in upper chambers containing 100 µL serum free medium with 10, 20 and 25 µM ormeloxifene 
treatments and allowed to migrate towards FBS gradient to lower chamber with 10% FBS for next 24 hours. Next, 
cells were fixed with 4% paraformaldehyde for 30 mins at room temperature and stained with crystal violet for next 
30 mins. Plates were then washed with running water to remove any excess staining. Cells in the upper chamber were 
completely removed by cotton swab while wet, plates were then air-dried and migrated cells were imaged by using 
light microscope at 100X. For invasion assay, the same protocol was used other than cells were plated in 24-transwell 
format from BD Biosciences in 500 µL serum free medium and ormeloxifene treatment was given next morning.
Agarose bead assay. For this experiment, 6-well plates were pre-coated with BSA-fibronectin. Cells 
(1 × 105) were trypsinized and mixed into a 0.2% low melting point agarose solution. About 30 µL of cells/agarose 
suspension was then plated onto fibronectin/BSA coated plates to form a bead. The agarose-beaded plates were 
placed at 4 °C for 10 mins to set the agarose beads. Complete growth medium containing drug treatments was 
slowly added from the edges of the wells so that beads were not disturbed and completely covered, and plates were 
then placed into a cell culture incubator at 37 °C with 5% CO2. At 0 and 24 hours, the plates were imaged under a 
phase-contrast microscope at 100X.
Real time cell proliferation, migration and invasion kinetic by xCELLigence. The xCELLigence 
system was used to measure the cellular events in real time as it is an electrical impedance-based method. Caski 
and SiHa cell lines for cell proliferation (8 × 103 per chamber) and for migration/invasion (3 × 104 per cham-
ber) were seeded and exposed to ormeloxifene and vehicle control (ETOH) treatments. Chamber plates were 
incubated in xCELLigence instrument unit at 37 °C with 5% CO2 for real time cell proliferation, migration and 
invasion measurements.
Morphology alteration. Both cells were plated at 1 × 106 per 100 mm dish and allowed to adhere overnight. 
Next day, cells were treated with a range of ormeloxifene (10, 20 and 25 μM) for 24 hours. Next, images were taken 
by using phase contrast microscopy at 200X for apoptosis like signs including cell rounding, cell shrinkage and 
membrane blebbing.
Mitochondrial membrane potential. Caski and SiHa cell lines were plated at 1 × 106/plate and allowed 
to attach overnight. Next day, cells were incubated with 2 mL phenol red free medium containing 50 nM TMRE 
(Thermo Fisher, MA, USA) at 37 °C for 20 mins, washed twice with PBS and exposed to ormeloxifene treatment 
for next 24 hours. At the indicated time, cells were washed twice with PBS, supplied with phenol red free medium 
and imaged using an Olympus microscope at 200X. For 0 hour images, cells were imaged right after the drug 
treatment. After imaging, cells were washed with PBS, trypsinized and analyzed with Accuri C6 flow cytometer 
(BD Biosciences, CA, USA) in FL2 channel.
Annexin V-7AAD staining. Caski and SiHa cell lines were plated (1 × 106/plate) and allowed to attach 
overnight. Next morning, cells were treated with different concentrations of ormeloxifene for 24 hours, both 
floaters and adherent cells were collected, washed twice with PBS and stained with Annexin V and 7AAD (BD 
Biosciences, CA, USA) 5 µL of each/100 µL of cell suspension for 20 mins in the dark at room temperature. After 
the incubation, cells were analyzed with Accuri C6 flow cytometer (BD Biosciences, CA, USA) in FL2 channel.
Cell cycle analysis. Caski and SiHa cell lines were plated in 100 mm dish at 1 × 106/plate and allowed to 
adhere overnight. Next day, cells were exposed to ormeloxifene treatment for 24 hours, trypsinized, washed 
twice with PBS, fixed with 70% ice cold ETOH and saved at −20 °C until further used. Cells were stained with 
Propidium Iodide solution (Sigma-Aldrich, St. Louis, MO, USA) 50 µg in 1 mL Telford reagent at 1 mL for 1 × 106 
cells for 4 hours at 4 °C in the dark and examined by Accuri C6 (BD Biosciences, CA, USA) flow cytometer in FL2 
channel. Data was further analyzed, and histograms were prepared using ModFit software.
Reactive oxygen species (ROS). Both cell lines were plated at 1 × 106/100 mm dish and allowed to adhere 
overnight. Next morning, cells were exposed to 25 µM ormeloxifene for 24 hours. After 24 hours, cells were 
washed with PBS, trypsinized, stained with 20 µM DCFH-DA (Sigma-Aldrich, St. Louis, MO, USA) (a dye that is 
widely used to detect generation of ROS) in 1 mL PBS and incubated for 20 mins at 37 °C. Cells were next analyzed 
with Accuri C6 flow cytometer (BD Biosciences, CA, USA) in FL2 channel.
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Immunoblotting. We selected Caski as our experimental model for this and next experiments as Caski 
contains almost 600 copies of viral genome67 and thus, represents the best working model for cervical cancer. 
Caski (1 × 106) cells were plated per 100 mm dish and allowed to attach overnight. Next day, cells were treated 
with different concentrations of ormeloxifene for 24 hours. After treatment, cells were collected in 2X SDS lysis 
buffer (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), sonicated and the protein concentration was normal-
ized using SYPRO- Orange (Molecular Probes, OR, USA). SDS-PAGE electrophoresis was done using 4–20% or 
10% gels and resolved proteins were transferred onto PVDF (BioRad, Hercules, CA, USA) membrane. HPV 16 
E6/E7 (Abcam, MA, USA), PI3K, Akt, pAkt, Rb, PTPN13, p21, Cyclin E and Cdk2 (Cell Signaling, MA, USA) 
and p53 (Santa Cruz, CA, USA) primary antibodies were used. The primary antibodies were detected by an 
HRP-secondary antibody (anti-mouse or anti-rabbit) followed by incubation with the Lumi-Light detection rea-
gent (Roche, Nutley, NJ, USA) and developed/imaged by using a UVP gel documentation system (all full-length 
blots are presented in Supplementary Information). Densitometry analyses of western blot bands were performed 
by using GelQuant software. Band intensity was normalized with the β -actin loading control and the expression 
level was compared to the vehicle control (ETOH).
Quantitative PCR. 1 × 106 Caski cells were plated per 100 mm dish and allowed to attach overnight. Next, 
cells were treated with ormeloxifene at 10 and 20 µM for 6 hours. After indicated time, adherent cells were col-
lected, and RNA was extracted with the Qiagen RNeasy kit (Qiagen Inc., Valencia, CA, USA). Reverse tran-
scription was performed with the High Capacity RNA to cDNA kit and amplified with SYBR Green PCR master 
mix (both from Applied Biosystems). The cDNA was amplified with primers specific for HPV16 E6, HPV16 E7 
and β2-microglobulin. E6-F: caaaccgttgtgtgatttgttaatta; E6-R: gctttttgtccagatgtctttgc; E7-F: ccggacacagcccat-
tacaa; E7-R: cgaatgtctacgtgtgtgctttg; β2M-F: tgagtatgcctgccgtgtga; β2M-R: tgatgctgcttacatgtctcgat63. Each 
reaction was performed in duplicate with a MyiQ single color real time PCR thermo cycler and analyzed with 
Genex (Microsoft Excel macro provided by BioRad). The results were first normalized to the endogenous control 
(β2-microglobulin) and then the expression level was scaled to the vehicle control (ETOH).
Radio-sensitization. In order to analyze the sensitization effects of ormeloxifene with radiation we utilized 
Caski cells. For cell proliferation, cells were seeded at 200,000 cells per well of 6-well plates and allowed to adhere 
overnight. Next day, cells were pretreated with 10 µM ormeloxifene for 6 hours and then exposed to 4Gy dose of 
radiation and maintained for another 24 hours. A Biological X-ray irradiator (Radiation Source, Alpharetta, GA, 
USA) was used to radiate the cells. After the indicated time cells were trypsinized, washed with PBS and counted 
with coulter counter (Beckman coulter counter, Life Sciences, IN, USA). Experiment was done in triplicate. For 
clonogenic potential, cells were seeded at 200 cells per well in 6-well plates and allowed to attach. Following day, 
cells were pretreated with ormeloxifene at 2, 4, 6 and 8 µM for 6 hours. After 6 hours, cells were exposed to radia-
tion at 4Gy dose. Next, cells were maintained for 12–14 days. On the day of termination, cells were washed, fixed 
in cold methanol and stained with hematoxylin (Thermo Fisher, MA, USA). Visible colonies (~50 cells) were 
counted manually. Each experiment was done in triplicates.
In vivo orthotopic tumoral study. In order to study the anti-tumoral properties of ormeloxifene, we devel-
oped an orthotopic mice model for cervical cancer. 4–6 weeks-old nu/nu female mice were purchased from 
Jackson laboratories and maintained in a pathogen-free environment. All experimental procedures were carried 
out in accordance with relevant guidelines and regulations as per provided in the protocols approved by the 
UTHSC Institutional Animal Care and Use Committee (UTHSC IACUC). We utilized 2 treatment groups named 
as PBS and ORM and each group had 6 mice. Caski cells (5 × 106 per mouse) were suspended in PBS and matrigel 
(BD Bioscience, CA, USA) at a 1:1 ratio. Cell suspension (5 × 106 cells in 100 µL) was injected orthotopically 
(direct) to the cervix of each mouse. Mice were monitored for the tumor development and once tumor reached 
the size of around 100 mm3, we started the drug treatment. Mice were treated with ORM and its vehicle control 
PBS at the concentration of 100 µg/mouse (ORM dose was selected based on our previously published study42) 
intra-peritoneally (i.p.) for the systemic therapy. Tumor volumes were measured by using a digital vernier caliper 
and calculated using the ellipsoid formula of tumor volume (mm3) = π/(6 × L × W × H), and survival was noted 
up to day 40. Mice survival was analyzed by Kaplan Meir analysis. Mice were sacrificed during the experiment if 
tumor volume/weight reached more than 10% of body weight (1.5–2.0 gram) or if mice lost more than 10% of wt. 
of their total body weight. On day 40, mice were euthanized, and tumors were observed and dissected.
Statistical methods. The data presented as mean ± standard error (SEM). Statistical analysis was deter-
mined by using an unpaired, two tailed student’s t-test. The results were considered significant if p < 0.05. All 
graphs were generated using GraphPad software.
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